Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia

Neurobiology of Disease

Volumn 25, Issue 3, 2007, Pages 506-513

  Burggraf, Dorothe ^a   Trinkl, Andreas ^a   Dichgans, Martin ^a   Hamann, Gerhard F ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Cerebral ischemia; Doxycycline; MMPs; Plasminogen activator; Rat; TIMP

Indexed keywords

COLLAGEN TYPE 4; DOXYCYCLINE; GELATINASE A; GELATINASE B; UROKINASE; WATER;

ANIMAL EXPERIMENT; ARTICLE; BASEMENT MEMBRANE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG INHIBITION; EXTRAVASATION; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION;

ANIMALS; ANTI-BACTERIAL AGENTS; BASEMENT MEMBRANE; BRAIN; BRAIN ISCHEMIA; DOXYCYCLINE; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEUROPROTECTIVE AGENTS; PLASMINOGEN ACTIVATORS; RATS; RATS, WISTAR; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 33847206486     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2006.10.013     Document Type: Article

References (45)

1. Asahi M., Asahi K., Jung J.C., del Zoppo G.J., Fini M.E., and Lo E.H. Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J. Cereb. Blood Flow Metab. 20 (2000) 1681-1689
2. Burggraf D., Martens H.K., Wunderlich N., Jager G., and Hamann G.F. Rt-PA causes a significant increase in endogenous u-PA during experimental focal cerebral ischemia. Eur. J. Neurosci. 20 (2004) 2903-2908
3. Burggraf D., Martens H.K., Liebetrau M., Vosko M.R., Dichgans M., and Hamann G.F. A new approach to reduce the number of animals used in experimental focal cerebral ischemia models. Neurosci. Lett. 386 (2005) 88-93
4. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., and Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6 (2000) 797-801
5. Clark W.M., Lessov N., Lauten J.D., and Hazel K. Doxycycline treatment reduces ischemic brain damage in transient middle cerebral artery occlusion in the rat. J. Mol. Neurosci. 9 (1997) 103-108
6. Courtman D.W., Franco C.D., Meng Q., and Bendeck M.P. Inward remodeling of the rabbit aorta is blocked by the matrix metalloproteinase inhibitor doxycycline. J. Vasc. Res. 41 (2004) 157-165
7. Fujimura M., Gasche Y., Morita-Fujimura Y., Massengale J., Kawase M., and Chan P.H. Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res. 842 (1999) 92-100
8. Fukuda S., Fini C.A., Mabuchi T., Koziol J.A., Eggleston L.L., and del Zoppo Jr. G.J. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke. 35 (2004) 998-1004
9. Golub L.M., Lee H.M., Ryan M.E., Giannobile W.V., Payne J., and Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res. 12 (1998) 12-26
10. Grenier D., Plamondon P., Sorsa T., Lee H.M., McNamara T., Ramamurthy N.S., Golub L.M., Teronen O., and Mayrand D. Inhibition of proteolytic, serpinolytic, and progelatinase-b activation activities of periodontopathogens by doxycycline and the non-antimicrobial chemically modified tetracycline derivatives. J. Periodontol. 73 (2002) 79-85
11. Griffin M.O., Jinno M., Miles L.A., and Villarreal F.J. Reduction of myocardial infarct size by doxycycline: a role for plasmin inhibition. Mol. Cell. Biochem. 270 (2005) 1-11
12. Hamann G.F., Liebetrau M., and Martens H.K. Microvascular basal lamina injury following experimental focal cerebral ischemia and reperfusion. J. Cereb. Blood Flow Metab. 22 (2002) 526-533
13. Hanemaaijer R., Visser H., Koolwijk P., Sorsa T., Salo T., Golub L.M., and van Hinsbergh V.W. Inhibition of MMP synthesis by doxycycline and chemically modified tetracyclines (CMTs) in human endothelial cells. Adv. Dent. Res. 12 (1998) 114-118
14. Heussen C., and Dowdle E.B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 102 (1980) 196-202
15. Hosomi N., Lucero J., Heo J.H., Koziol J.A., Copeland B.R., and del Zoppo G.J. Rapid differential endogenous plasminogen activator expression after acute middle cerebral artery occlusion. Stroke 32 (2001) 1341-1348
16. Jantzie L.L., Cheung P.Y., and Todd K.G. Doxycycline reduces cleaved caspase-3 and microglial activation in an animal model of neonatal hypoxia-ischemia. J. Cereb. Blood Flow Metab. 25 (2005) 314-324
17. Jonat C., Chung F.Z., and Baragi V.M. Transcriptional downregulation of stromelysin by tetracycline. J. Cell. Biochem. 60 (1996) 341-347
18. Kloss C.U., Thomassen N., Fesl G., Martens K.H., Yousri T.A., and Hamann G.F. Tissue-saving infarct volumetry using histochemistry validated by MRI in rat focal ischemia. Neurol. Res. 24 (2002) 713-718
19. Koistinaho M., Malm T.M., Kettunen M.I., Goldsteins G., Starckx S., Kauppinen R.A., Opdenakker G., and Koistinaho J. Minocycline protects against permanent cerebral ischemia in wild type but not in matrix metalloprotease-9-deficient mice. J. Cereb. Blood Flow Metab. 25 (2005) 460-467
20. Lee H.M., Golub L.M., Cao J., Teronen O., Laitinen M., Salo T., Zucker S., and Sorsa T. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr. Med. Chem. 8 (2001) 257-260
21. Lijnen H.R. Elements of the fibrinolytic system. Ann. N. Y. Acad. Sci. 936 (2001) 226-236
22. Liu J., Xiong W., Baca-Regen L., Nagase H., and Baxter B.T. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J. Vasc. Surg. 38 (2003) 1376-1383
23. Manning M.W., Cassis L.A., and Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 483-488
24. Mignatti P. Cellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int., Suppl. 49 (1995) 12-14
25. Miyazawa T., Bonnekoh P., and Hossmann K.-A. Temperature effect on immunostaining of microtubule-associated protein 2 and synaptophysin after 30 minutes of forebrain ischemia in rat. Acta Neuropathol. 85 (1993) 526-532
26. Morimoto N., Shimazawa M., Yamashima T., Nagai H., and Hara H. Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res. 1044 (2005) 8-15
27. Nelson K.K., Subbaram S., Connor K.M., Dasgupta J., Ha X.F., Meng T.C., Tonks N.K., and Melendez J.A. Redox-dependent matrix metalloproteinase-1 expression is regulated by JNK through Ets and AP-1 promoter motifs. J. Biol. Chem. 281 (2006) 14100-14110
28. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1998), Academic Press, San Diego
29. Prall A.K., Longo G.M., Mayhan W.G., Waltke E.A., Fleckten B., Thompson R.W., and Baxter B.T. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J. Vasc. Surg. 35 (2002) 923-929
30. Pyo R., Lee J.K., Shipley J.M., Curci J.A., Mao D., Ziporin S.J., Ennis T.L., Shapiro S.D., Senior R.M., and Thompson R.W. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest. 105 (2000) 1641-1649
31. Rijken D.C. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Bailliere's Clin. Haematol. 8 (1995) 291-312
32. Roach D.M., Fitridge R.A., Laws P.E., Millard S.H., Varelias A., and Cowled P.A. Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur. J. Vasc. Endovasc. Surg. 23 (2002) 260-269
33. Rosenberg G.A. Ischemic brain edema. Prog. Cardiovasc. Dis. 42 (1999) 209-216
34. Rosenberg G.A., Navratil M., Barone F., and Feuerstein G. Proteolytic cascade enzymes increase in focal cerebral ischemia in rat. J. Cereb. Blood Flow Metab. 16 (1996) 360-366
35. Sadowski T., and Steinmeyer J. Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm. Res. 50 (2001) 175-182
36. Schreiber S.S., Tan Z., Sun N., Wang L., and Zlokovic B.V. Immunohistochemical localization of tissue plasminogen activator in vascular endothelium of stroke-prone regions of the rat brain. Neurosurgery 43 (1998) 909-913
37. Sorsa T., Lindy O., Konttinen Y.T., Suomalainen K., Ingman T., Saari H., Halinen S., Lee H.M., Golub L.M., Hall J., et al. Doxycycline in the protection of serum alpha-1-antitrypsin from human neutrophil collagenase and gelatinase. Antimicrob. Agents Chemother. 37 (1993) 592-594
38. Sutton T.A., Kelly K.J., Mang H.E., Plotkin Z., Sandoval R.M., and Dagher P.C. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury. Am. J. Physiol.: Renal Physiol. 288 (2005) F91-F97
39. Takahashi S., Sato T., Ito A., Ojima Y., Hosono T., Nagase H., and Mori Y. Involvement of protein kinase C in the interleukin 1 alpha-induced gene expression of matrix metalloproteinases and tissue inhibitor-1 of metalloproteinases (TIMP-1) in human uterine cervical fibroblasts. Biochim. Biophys. Acta 1220 (1993) 57-65
40. Uitto V.J., Firth J.D., Nip L., and Golub L.M. Doxycycline and chemically modified tetracyclines inhibit gelatinase A (MMP-2) gene expression in human skin keratinocytes. Ann. N. Y. Acad. Sci. 732 (1994) 140-151
41. Wang C.X., Yang T., and Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res. 963 (2003) 327-329
42. Webster G.F., Toso S.M., and Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Involvement of protein kinase C. Arch. Dermatol. 130 (1994) 748-752
43. Xu L., Fagan S.C., Waller J.L., Edwards D., Borlongan C.V., Zheng J., Hill W.D., Feuerstein G., and Hess D.C. Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol. 26 (2004) 4-7
44. Yrjanheikki J., Keinanen R., Pellikka M., Hokfelt T., and Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15769-15774
45. Yrjanheikki J., Tikka T., Keinanen R., Goldsteins G., Chan P.H., and Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 13496-13500